Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine

Surgery

Volumn 141, Issue 3, 2007, Pages 346-353

  Tokunaga, Yukihiko ^a   Sasaki, Hirokazu ^a   Saito, Tohru ^a  

^a Japan Post   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; OROTATE PHOSPHORIBOSYLTRANSFERASE; TEGAFUR; UFT; URACIL;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TEGAFUR; TUMOR MARKERS, BIOLOGICAL; URACIL;

EID: 33847613374     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2006.06.025     Document Type: Article

References (37)

1. Moertel C.G. Chemotherapy for colorectal cancer. N Engl J Med 330 (1994) 1136-1142
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10 (1992) 896-903
3. Peters G.J., Laurensse E., Leyva A., et al. Sensitivity of human, murine, and rat cells to 5-fluorouraicl and 5′-deoxy-5-fluorouracil in relation to drug-metabolizing enzymes. Cancer Res 46 (1986) 20-28
4. Peters G.J., Groeningen C.J., Laurensse E.J., and Pinedo H.M. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68 (1991) 1903-1909
5. Yasue K., Usami Y., Hashizume H., et al. Metabolism of fluoropyrimidine in cancer patients (Part II). Jpn J Clin Pharmacol Ther 18 (1987) 689-698
6. Heggie G.D., Sommadossi J.P., Cross D.S., Husster W.J., and Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47 (1987) 2203-2206
7. Tokunaga Y., Hosogi H., Hoppou T., Nakagami M., Tokuka A., and Ohsumi K. Prognostic value of thymidine phosphorylase/PD-ECGF in advanced colorectal cancer after surgery: evaluation with a new monoclonal antibody. Surgery 131 (2002) 541-547
8. Komuro Y., Watanabe T., Tsuno N., et al. The usefulness of immunohistochemical evaluation of dihydropyrimidine dehydrogenase for rectal cancer treated with preoperative radiotherapy. Hepatogastroenterology 50 (2003) 906-911
9. Tokunaga Y., Takahashi K., and Saito T. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Hepatogastroenterology 52 (2005) 1715-1721
10. Inaba M., Mitsuhashi J., Sawada H., et al. Reduced activity of anabolizing enzymes in 5-fluorouracil resistant human stomach cancer cells. Jpn J Cancer Res 87 (1996) 212-220
11. Fukushima M., Nomura H., Murakami Y., et al. Estimation of pathway of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo. Jpn J Cancer Chemother 23 (1996) 721-731
12. Koyama F., Sawada H., Fujii H., et al. Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. Eur J Cancer 36 (2000) 2403-2410
13. Sakamoto K., Sugimoto Y., Miyadera K., Oka T., and Fukushima M. Preparation of anti-OPRT antibody for immunochemical detection. Gan To Kagaku Ryoho 32 (2005) 653-658
14. Kamoshida S., Sakamoto N., Matsuoka H., et al. Heat-assisted stretching of paraffin section on hot plate weakens immunoreactivity of orotate phosphoribosyltransferase. Acta Histochem Cytochem 38 (2005) 69-74
15. Okabe H., Arakawa K., Takechi T., and Fukushima M. Expression of recombinant human dihydropyrimidine dehydrogenase and its application to the preparation of anti-DPD antibodies for immunochemical detection. Jpn J Cancer Chemother 27 (2000) 891-899
16. Tokunaga Y., Nakagami M., Tokuka A., and Ohsumi K. Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody. Anticancer Res 23 (2003) 1763-1768
17. Japanese Research Society for Cancer of Colon and Rectum. General rules for clinical and pathological studies on cancer of colon, rectum, and anus. 5th ed. (1994), Kanehara and Co. Ltd, Tokyo (Jpn)
18. Kammerer U., Kapp M., Gussel A.M., et al. A new rapid immunohistochemical staining technique using the Envision antibody Complex. J Histochem Cytochem 49 (2001) 623-630
19. Sabattini E., Bisgaard K., Ascani S., et al. The EnVision+ system: anew immunohistochemical method for diagnosis and research. Critical comparison with the APPAP, Chem Mate, CSA, LABC, and SABC technique. J Clin Pathol 51 (1998) 506-511
20. Bobrow M., Harris T.D., Shaughnessy K.J., and Litt G.J. Catalyzed reporter deposition, a novel method of signal amplification: application to immunoassays. J Immunol Meth 125 (1989) 279-284
21. Lee T.E. Statistical methods for survival data analysis. 2nd ed. (1992), John Wiley & Sons, New York
22. Breslow N.E., and Day N.E. Statistical methods in cancer research. Volume II: the design and analysis of cohort studies. IARC Sci Publ (1987) 1-406
23. Katsumata K., Tomioka H., Sumi T., et al. Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients colon carcinoma by two different dosage regimens. Cancer Chemother Pharmacol 51 (2003) 155-160
24. Fukushima M., Nomura Y., Murakami Y., Shirasaka T., and Aiba K. Analysis of phosphorylation pathway of 5-fluorouracil in human cancer cell. Gan to Kagaku Ryoho 6 (1996) 721-731
25. Cuq P., Rouquet C., Evrard A., Ciccolini J., Vian L., and Cano J.P. Fluoropyrimidine sensitivity of human MCF-7 breast cancer cells stably transfected with human uridine phosphorylase. Br J Cancer 84 (2001) 1677-1680
26. Schwartz P.M., Moir R.D., Hyde C.M., Turek P.J., and Handeschumacher R.E. Role of uridine phosphorylase in the anabosim of 5-fluorouracil. Biochem Pharmacol 34 (1985) 3585-3589
27. Maehara Y., Sakaguchi Y., Kusumoto T., Kusumoto H., and Sugimachi K. Species differences in substrate specificity of pyrimidine nucleoside phosphorylase. J Surg Oncol 42 (1989) 184-186
28. Uchida M., and Nakamura T. Metabolism of 5-fluorouracil in tumor cell. Purine and Pyrimidene Metabolism (in Japanese) 15 (1991) 122-129
29. Ochiai T., Sugitani M., Nishimura K., Noguchi H., Watanabe T., Sengoku H., Kihara A., and Okano M. [Expression and pathophysiologic features of orotate phosphoribosyl transferase activity (OPRT) in gastric carcinoma]. Gan To Kagaku Ryoho 28 (2001) 345-350
30. Ochiai T., Sugitani M., Nishimura K., et al. Correlation between clinical pathophysiologic factors and expression of orotate phosphoribosyl transferase activity (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer. Gan To Kagaku Ryoho 29 (2002) 413-420
31. Takemura M., Osugi H., Lee S., et al. Choice of chemotherapeutic drugs for colorectal cancers by DPD and OPRT activities in cancer tissues. Gan To Kagaku Ryoho 31 (2004) 1053-1056
32. Ichikawa W., Uetake H., Shirota Y., et al. Both gene expression for orotate phosphoribosyl transferase and its ratio for dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89 (2003) 1486-1492
33. Isshi K., Sakuyama T., Gen T., et al. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemotherapy to 5-FU. Int J Clin Oncol 7 (2002) 335-342
34. Metzger R., Danenberg K., Leichman C.G., et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouraicl. Clin Cancer Res 4 (1998) 2371-2376
35. Evrard A., Cuq P., Ciccolini J., Vian L., and Cano J.P. Increased cytotoxicity and by stander effect of 5-fluorouracil and 5-deoxy-5-fluorouracil in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 80 (1999) 1726-1733
36. Schwartz E.L., Baptiste N., Megati S., Wadler S., and Otter B.A. 5-Ethoxy-2′-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fuorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression. Cancer Res 55 (1995) 3543-3550
37. Furukawa T., Yoshimura A., Sumizawa T., Haraguchi M., Akiyama S., Fukui K., Ishizawa M., and Yamada Y. Angiogenic factor. Nature 356 (1992) 668